{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_7491543_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"006-056-504-351-981"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11882,"type":"PATENT","title":"Yeshiva University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2927,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8485,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:Yeshiva Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1369
Search Applicants and Owners separately:Yeshiva Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1369
25)cognitive dysfunction. While LDL particle size had no relationship withMini Mental scoring, HDL particle size demonstrated a significantrelationship.MMSE >25MMSE <25Variable(N = 68)(N = 71)P ValueHDL mg/dL60.4 +/− 2.548.3 +/− 1.70.0001Large HDL mg/dL39.9 +/− 1.1729.6 +/− 1.490.0001(% Total HDL)HDL Size (nm)9.51 +/− 0.049.28 +/− 0.050.0001LDL mg/dL113.5 +/− 4.21116.8 +/− 4.41NSLarge LDL mg/dL69.5 +/− 3.0161.8 +/− 4.43NS(% Total LDL)LDL Size (nm)21.0 +/− 0.0521.1 +/− 0.09NSVLDL mg/dL72.8 +/− 4.880.2 +/− 4.7NSData are expressed as mean ± S.D.MMSE, Mini Mental Standard Exam. TABLE 9Percent of subjects with exceptional longevity according to favorablelipoprotein profile and cognitive function (by MMSE). Subjects wereassigned according to those with high HDL levels (>50 mg/dL in femaleand >40 mg/dL in male) (113), large HDL particle size (>8.8 nm),large LDL particle size (>21.3 nm), low LDL level (>130 mg/dL).Minimental>25≦25P valueLow HDL (%)26510.0002High HDL (%)7449HDL size ≦8.8 (%)8150.05HDL size >8.8 (%)9285Low LDL (%)28360.22High LDL (%)7264LDL size ≦21.3 (%)25390.03LDL size >21.3 (%)7561 TABLE 10Height, and IGF-1 and IGF binding protein-3 (BP-3) plasma levels in Proband,Offspring and their Control, and in a General Control group.OffspringControlProbandGeneral ControlFemaleMaleFemaleMaleFemaleMaleFemaleMaleN = height143134653913643443418Maximal63.469.564.469.462.566.860.566.9Height(2.26)(2.57)(2.56)(2.24)(2.33)(2.87)(inches)N = IGF-1654521147826——IGF-1130*163115163111*87.5*——(ng/ml)(57)(51.4)(52.6)(61.2)(51.8)(39.1)BP-313569481389860934531——(ng/ml)(1857)(1498)(1815)(1393)(1416)(984)*p < 0.01 vs. control.Data presented as Mean and (S.D.). TABLE 11Lipoprotein concentrations and particle sizes in offspring with high (OADIPOQH)and low (OADIPOQL) adiponectin levels.FemalesP valueMalesP valueOADIPOQLOADIPOQHOADIPOQOADIPOQLOADIPOQHOADIPOQNumber of subjects8032L vs. H6842L vs. HAge (years)69.4 (0.7)69.7 (0.8)0.869.7 (0.6)71.1 (1.1)0.29Adiponectin (ug/mL)10.8 (0.39)22.9 (0.7)0.00016.48 (0.3)18.2 (0.68)0.0001BMI26.4 (0.5)23.7 (0.5)0.00327.2 (0.4)25.8 (0.4)0.08% Fat34.6 (0.84)31.5 (0.94)0.0324.5 (0.6)23.8 (0.94)0.53Cholesterol (mg/dL)222 (4.1)226 (5.51)0.5192 (3.45)197 (6.45)0.5Triglyceride (mg/dL)161 (9.36)116 (10.9)0.005171 (11.8)124 (11.7)0.02HDL (mg/dL)65 (1.7)77 (2.8)0.000251 (1.7)59 (2.3)0.007Large HDL particle51 (1.7)64 (2.0)0.000143 (1.9)52 (2.3)0.004size (% of Total)Large LDL particle64 (3.3)87 (2.7)0.000147 (3.5)66 (4.1)0.0007size (% of Total)HOMA5 (0.7)1.9 (0.9)0.018.6 (1.1)5.7 (1.9)0.1% with metabolic20100.0526120.04syndromeData are expressed as mean (SE).OADIPOQH defined as ADIPOQ levels >1 SD above the mean for age-matched control subjects TABLE 12CETP I405V genotype and lipoprotein characteristic and plasma CETPlevels in families with exceptional longevity and controls.VV vs. IICETP I405V genotypegenotypesVariableVVIVIIP valueHDL(mg/dL)57(18)55(16)55(16)0.53Large HDL56(16)60(14)60(15)0.1(% Total)HDL Size(nm)9.28(0.56)9.09(0.52)9.07(0.48)0.02LDL(mg/dL)114(35)120(30)123(34)0.16Large LDL67(25)58(24)56(28)0.02(% Total)LDL Size(nm)21.29(0.67)20.98(0.63)20.88(0.81)0.002CETP(μg/mL)1.65(0.59)1.92(0.65)1.99(0.72)0.0008Data are expressed as mean ± S.D. TABLE 13Comparison of lipoprotein traits in offspring and control groups by APOC3 C(-641)A genotype.CA/AA Control vs.Control APOC-3Offspring APOC-3OffspringCCCA/AApCCCA/AAppFemaleN11642670HDL size (nm)9.47 (0.09)9.27 (0.07)0.209.33 (0.07)9.43 (0.06)0.440.04HDL (mg/dl)77 (4)61 (2)0.00772.7 (3.09)68.7 (1.9)0.270.009LDL size (nm)21.60 (0.11)21.11 (0.09)0.0421.7 (0.05)21.6 (0.07)0.440.0006LDL (mg/dl)104 (9)132 (4)0.01129 (7.98)118 (4.19)0.210.02Triglycerides (mg/dl)88 (12)115 (5)0.04117 (12.1)114 (6.97)0.840.51Cholesterol (mg/dl)183 (13)208 (5)0.04210 (9.63)196 (5.5)0.190.07TG/HDL1.21 (0.19)2.09 (0.13)0.0071.73 (0.2)1.67 (0.12)0.810.01ApoA-1 (mg/dl)173 (6.41)175 (4.01)0.82185 (5.71)173 (2.87)0.080.76ApoB (mg/dl)102 (9.06)102 (3.27)0.96105 (5.07)104 (2.01)0.850.71APOC3 (mg/dl)8.9 (1.6)10.97 (0.65)0.059.4 (1.3)11 (0.6)0.140.9CETP levels (mg/dl)1.84 (0.2)2.14 (0.09)0.21.9 (0.1)2.08 (0.07)0.220.8MaleN9462248HDL size (nm)8.90 (0.13)9.02 (0.06)0.339.03 (0.09)9.16 (0.06)0.350.1HDL (mg/dl)50 (5)45 (1)0.2151 (3)55 (2)0.330.0005LDL (mg/dl)103 (11)107 (4)0.67106 (6)101 (4)0.540.04LDL size (nm)21.00 (0.18)20.80 (0.08)0.4421 (0.18)21.2 (0.1)0.270.09Triglycerides (mg/dl)104 (10)111 (5)0.56149 (15)113 (10)0.050.54Cholesterol (mg/dl)165 (15)170 (5)0.68172 (8)166 (6)0.570.24TG/HDL2.24 (0.29)2.65 (0.18)0.323.41 (0.43)2.19 (0.21)0.020.07ApoA-1 (mg/dl)143 (11)136 (4.12)0.58158 (5.36)140 (2.77)0.0060.32ApoB (mg/dl)85.4 (9.61)93.7 (2.92)0.34101 (3.37)96.4 (2.01)0.30.52APOC3 (mg/dl)7.3 (1.6)10.2 (0.9)0.058.6 (1.5)10.3 (0.76)0.250.85CETP levels (mg/dl)1.49 (0.34)1.76 (0.1)0.371.71 (0.12)1.9 (0.07)0.20.5CC: homozygous for -641 C;CA/AA: homozygous and heterozygous for (-641)A.Results presented as mean (SE). REFERENCES 1. Barzilai N, Shuldiner A R. Searching for human longevity genes: The future history of gerontology in the post-genomic era. Journal of Gerontology. 56A:M83-M87, 2001.2. Perls T T, Bubrick E, Wager C G, Vijg J, Kruglyak L. Sibling of centenarians live longer. Lancet. 351:1560, 1998.3. Puca A A, Daly M J, Brewster S J, Matise T C, Barrett J, Shea-Drinkwater M, et al. A genome-wide scan for linkage to human exceptional longevity identifies a locus on chromosome 4. Proc Natl Acad Sci USA. 98:10505-8, 2001.4. Atzmon G, Schechter C, Greiner W, Davidson D, Rennert G, Barzilai N. Clinical Phenotype of Families with Longevity. J Am Geriat Soc 52(2):274-277, 2004.5. Evert J, Lawler E, Perls T: Morbidity Profiles of Centenarians: Survivors, Delayers and Escapers. J. Gerontol. A. Biol. Sci. Med. Sci. 58(3): 232-7, 2003.6. Perls T T, Wilmoth J, Levenson R, Drinkwater M, Cohen M, Bogan H, et al. Life-long sustained mortality advantage of siblings of centenarians. Proc Natl Acad Sci USA. 2002; 99(12):8442-7.7. Barzilai N, Gabriely I, Gabriely M, Iankowitz N, Sorkin J D. Offspring of centenarians have a favorable lipid profile. J Am Geriatr Soc. 2001; 49: 76-9.8. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation. 1997 Jul. 1; 96(1):37-43.9. Wilson, P. W., K. M. Anderson, et al. (1994). Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol 49(6): M252-7.10. U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Survey, 1988-1994, NHANES III Second Laboratory Data File (CD-ROM series 11, No. 2A).11. Malaguarnera M, Giugno I, Ruello P, Rizzo M, Panebianco M P, Pistone G, Tomasello F B. Lipid profile variations in a group of healthy elderly and centenarians. Eur Rev Med Pharmacol Sci. 1998 March-April; 2(2):75-9.12. Pepe, G., V. Di Perna, et al. (1998). In search of a biological pattern for human longevity: impact of apo A-IV genetic polymorphisms on lipoproteins and the hyper-Lp(a) in centenarians. Atherosclerosis 137(2): 407-17.13. Thillet J, Doucet C, Chapman J, Herbeth B, Cohen D, Faure-Delanef L. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians. Atherosclerosis. 1998 February; 136(2):389-94.14. Atzmon G, Gabriely I, Greiner W, Davidson D, Barzilai N: Plasma HDL Levels Highly Correlate with Cognitive Function in Exceptional Longevity. J Gerontol A Biol Sci Med Sci. 2002. 57:M712-5.15. Lancaster, J. M., M. E. Carney, et al. (1997). BRCA 1 and 2—A Genetic Link to Familial Breast and Ovarian Cancer.” Medscape Womens Health 2(2): 7.16. Verghese J, Lipton R B, Hall C B, Kuslansky G, Katz M J, Buschke H. Abnormality of gait as a predictor of non-Alzheimer's dementia. N Engl J Med 2002; 347(22):1761-8.17. Folstein M F, Folstein S E, McHugh P R. “Mini-mental state” A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975; 12:189-198.18. Otvos J D, Jeyarajah E J, Bennett D W. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem. 37(3):377-86, 1991.19. Otvos J D, Jeyarajah E J, Bennett D W, Krauss R M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992 September; 38(9):1632-8.20. Kraus W E, Houmard J A, Duscha B D, Knetzger K J, Wharton M B, McCartney J S, Bales C W, Henes S, Samsa G P, Otvos J D, Kulkarni K R, Slentz C A. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J. Med. 2002 Nov. 7; 347(19):1483-92.21. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais G R, et al. 1997. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95:69-75.22. Austin M A. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep. 2000 May; 2(3):200-7. Review.23. Kamigaki A S, Siscovick D S, Schwartz S M, Psaty B M, Edwards K L, Raghunathan T E, Austin M A. Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am J Epidemiol. 2001 May 15; 153(10):939-45.24. Bjornheden T, Babyi A, Bondjers G, Wiklund O. 1996. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123:43-5625. Anber V, Millar J S, McConnell M, Shepherd J, Packard C J. 1997. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler. Thromb. Vasc. Biol. 17:2507-1426. Chait A, Brazg R L, Tribble D L, Krauss R M. 1993. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein, pattern B. Am. J. Med. 94:350-56.27. Liu M L, Ylitalo K, Vakkilainen J, Nuotio I, Valkonen M, Lahdenpera S, Viikari J, Taskinen M R. Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes. Ann Med. 2002; 34(1):48-54.28. Vakkilainen J, Makimattila S, Seppala-Lindroos A, Vehkavaara S, Lahdenpera S, Groop P H, Taskinen M R, Yki-Jarvinen H. Endothelial dysfunction in men with small LDL particles. Circulation. 2000 Aug. 15; 102(7):716-21.29. Superko H R. Small, dense low-density lipoprotein subclass pattern B: issues for the clinician. Curr Atheroscler Rep. 1999 July; 1(1):50-7. Review.30. Campos H, Blijlevens E, McNamara J P, Ordovas J M, Posner B M, et al. 1992. LDL particle size distribution. Results from the Framingham Offspring Study. Arteriosclerosis. Thromb. 12:1410-19.31. Asztalos B F, Horvath K V, McNamara J R, Roheim P S, Rubinstein J J, Schaefer E J. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res. 2002 October; 43(10):1701-7.32. Pascot A, Lemieux I, Bergeron J, Tremblay A, Nadeau A, Prud'homme D, Couillard C, Lamarche B, Despres J P. HDL particle size: a marker of the gender difference in the metabolic risk profile. Atherosclerosis. 2002 February; 160(2):399-406.33. Barzilai, N. and G. Gupta (1999). Revisiting the role of fat mass in the life extension induced by caloric restriction. J Gerontol A Biol Sci Med Sci 54(3): B89-96; discussion B97-8.34. Calabresi, L, G. Francéschini, C. R. Sirtori, A. De Palma, M. Saresella, P. Ferrante and D. Taramelli Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem. Biophys. Res. Commun. 238 (1997), pp. 61-6.35. Nofer, J. R. M. Walter, B. Kehrel, S. Wierwille, M. Tepel, U. Seedorf and G. Assmann, HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler. Thromb. Vasc. Biol. 18 (1998), pp. 861-869.36. Witztum J. L. and J. A. Berliner, Oxidized phospholipids and isoprostanes in atherosclerosis. Curr. Opin. Lipidol. 9 (1998), pp. 441-448.37. Lesnik, P, A. Vonica, M. Guerin, M. Moreau and M. J. Chapman, Anti-coagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscl. Thromb. 13 (1993), pp. 1066-107.38. Levin, E. G. L. A. Miles, G. M. Fless, A. M. Scanu, P. Baynham, L. K. Curtiss and E. F. Plow, Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler. Thromb. 14 (1994), pp. 438-44.39. Libby P. Managing the risk of atherosclerosis: the role of high-density lipoprotein. Am J Cardiol. 2001 20; 88(12A):3N-8N. Review.40. Rader D J, Maugeais C. Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. Mol Med Today. 2000 April; 6(4):170-5. Review.41. Merched A, Xia Y, Visvikis S, Serot J M, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein A-I concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiology of Aging. 2000; 21:27-3042. Kawano M, Kawakami M, Otsuka M, Yashima H, Yaginuma T, Ueki A. Marked decrease of plasma apolipoprotein A-I and A-II in Japanese patients with late-onset non-familial Alzheimer's disease. Clin Chim Acta. 1995; 239:209-211.43. Kuriyama M, Takahashi K, Yamono T, Hokezu Y, Togo S, Osame M, Igakura T. Low levels of serum apolipoprotein a1 and a2 in senile dementia. Jpn J Psychiatry Neurol. 1994; 48:589-5938.44. van Exel E, de Craen A J, Gussekloo J, Houx P, Bootsma-van der Wiel A, Macfarlane P W, Blauw G J, Westendorp R G. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol. 2002 June; 51(6):716-21.45. Yamashita, S., D. L. Sprecher, N. Sakai, Y. Matsuzawa, S. Tarui, and D. Y. Hui. 1990. Accumulation of apolipoproteinE-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J. Clin. Invest. 86: 688-695.46. Arai, T., T. Tsukada, T. Murase, and K. Matsumoto. 2000. Particle size analysis of high density lipoproteins in patients with genetic cholesteryl ester transfer protein deficiency. Clin. Chim. Acta. 301: 103-117.47. Sakai N, Yamashita S, Hirano K, Ishigami M, Arai T, et al. 1995. Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency. Eur. J. Clin. Invest. 25:332-39.48. Zak Z, Lagrost L, Gautier T, Masson D, Deckert V, Duverneuil L, De Barros J P, Le Guern N, Dumont L, Schneider M, Risson V, Moulin P, Autran D, Brooker G, Sassard J, Bataillard A. Expression of simian CETP in normolipidemic Fisher rats has a profound effect on large sized apoE-containing HDL. J Lipid Res. 2002 December; 43(12):2164-2171.49. Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Fairwell T, et al. 1995. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J. Clin. Invest. 96:1573-81.50. Carr M C, Ayyobi A F, Murdoch S J, Deeb S S, Brunzell J D. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol. 2002 Apr. 1; 22(4):667-73.51. Juo S H, Han Z, Smith J D, Colangelo L, Liu K. Promoter polymorphisms of hepatic lipase gene influence HDL(2) but not HDL(3) in African American men: CARDIA study. J Lipid Res. 2001 February; 42(2):258-64.52. Zambon, A., S. S. Deeb, J. E. Hokanson, B. G. Brown, and J. D. Brunzell. 1998. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler. Thromb. Vasc. Biol. 18: 1723-1729.53. Agerholm-Larsen B, Nordestgaard B G, Steffensen R, Jensen G, Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 2000 Apr. 25; 101(16):1907-12.54. Brousseau M E, O'Connor J J Jr, Ordovas J M, Collins D, Otvos J D, Massov T, McNamara J R, Rubins H B, Robins S J, Schaefer E J. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol. 2002 Jul. 1; 22(7):1148-54.55. Kuivenhoven J A, de Knijff P, Boer J M, Smalheer H A, Botma G J, et al. 1997. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 17:560-68.56. Wilund K R, Ferrell R E, Phares D A, Goldberg A P, Hagberg J M. Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype. Metabolism. 2002 June; 51(6):774-8.57. Schaefer E J, Lamon-Fava S, Cohn S D, Schaefer M M, Ordovas J M, Castelli W P, Wilson P W. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994 May; 35(5):779-92.58. Koren-Morag N, Tanne D, Graff E, Goldbourt U. Related Articles, Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch Intern Med. 2002 13; 162(9):993-959. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul. 6; 360(9326):7-22.60. Nissen, H., A. B. Hansen, et al. (1994). Detection of a single base deletion in codon 424 of the low density lipoprotein receptor gene in a Danish family with familial hypercholesterolemia. Atherosclerosis 111(2): 209-15.61. Descamps, O., J. C. Hondekijn, et al. (1997). High prevalence of a novel mutation in the exon 4 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia in Belgium. Clin Genet 51(5): 303-8.62. Diaz, M. N. B. Frei, J. A. Vita and J. F. Keaney, Anti-oxidants and atherosclerotic heart disease. N. Engl. J. Med. 337 (1997), pp. 408-416.63. Austin M A, King M C, Vranizan K M, Newman B, Krauss R M. 1988. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am. J. Hum. Genet. 43:838-46.64. Coresh J, Kwiterovich P O Jr, Smith H H, Bachorik P S. 1993. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J. Lipid Res. 34:1687-97.65. Gardner C D, Fortmann S P, Krauss R M. 1996. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875-8.66. Stampfer M J, Krauss R M, Ma J, Blanche P J, Holl L G, et al. 1996. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-88.67. Blake G J, Otvos J D, Rifai N, Ridker P M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002 Oct. 8; 106(15):1930-7.68. Tangney C C, Mosca L J, Otvos J D, Rosenson R S. Oral 17beta-estradiol and medroxyprogesterone acetate therapy in postmenopausal women increases HDL particle size. Atherosclerosis. 2001 April; 155(2):425-30.69. Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R. X Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am J Cardiol. 2002 Oct. 17; 90(8A):22i-29i.70. Bruce C, Sharp D S, Tall A R. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res. 1998 May; 39(5):1071-8.71. Tailleux A and Fruchart J C. HDL heterogeneity and atherosclerosis. Critical Reviews in Clinical Laboratory Sciences. 33(3) 163-201: 1996.72. Barbagallo C M, Averna M R, Fradà G, Noto D, Cavera G, and Notarbartolo A. Lipoprotein profile and high-density lipoproteins: subfractions distributions in centenarians. Gerontology 44: 106-110, 1998.73. Arai Y, Hirose N, Kawamura M, Homma S, Hasegawa H, Ishida H, Osono Y, Shimizu K, Nakarnura Y, Sakamoto T, Tada N and Homma A. Lipid and lipoprotein profile of Japanese centenarians—high prevalence of hypo beta lipoproteinemia. Nippon Ronen Igakkai Zasshi. 34(3): 202-8, 1997 [article in Japanese].74. Ettinger W H Jr, Verdery R B, Wahl P W, Fried L P. High density lipoprotein subfractions in older people. J. Gerontol. 49(3): M116-22, 1994.75. Cheng, S., Grow, M., Pallaud, C., Klitz, W., Erlich, H., Visvikis, S., Chen, J., Pullinger, C., Malloy, M., Siest, G., Kane, J. (1999) A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Research 9: 936-949.76. LipoScience-Clinicians-Research Services-Domestic, http://www.liposcience.com/clin_rs.htm (as available on Jan. 14, 2003).77. Handbook of Lipoprotein Testing, Chapter 31: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy, J. D. Otvos, AACC Press, Washington D.C., 2000, 2nd edition, pp 609-623.78. LipoScience-Clinicians-NMR LipoProfile-Test Information, http://www.liposcience.com/clin_nmr.htm (as available on Jan. 14, 2003).79. von Eckardstein, A. Y. Huang and G. Assmann, Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr. Opin. Lipidol. 5 (1994), pp. 404-416.80. Austin M A, King M C, Vranizan K M, Krauss R M. 1990. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82:495-506.81. Krauss R M. Dietary and genetic effects on low-density lipoprotein heterogeneity. Annu Rev Nutr. 2001; 21:283-95. Review82. Sugano, M., N. Makino, S. Sawada, S. Otsuka, M. Watanabe, H. Okamoto, M. Kamada, and A. Mizushima. 1998. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273: 5033-5036.83. Okamoto, H., F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai. 2000. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406: 203-207.84. Hirano, K., S. Yamashita, and Y. Matsuzawa. 2000. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr. Opin. Lipidol. 11: 589-596.85. Francone O L, Royer L, Haghpass M. 1996. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J. Lipid Res. 37:1268-77.86. Funke H, Wiebusch H, Fuer L, Muntoni S, Schulte H, Assmann G. Identification of mutations in the cholesterol ester transfer protein in Europeans with elevated high density lipoprotein cholesterol. Circulation. 1994; 90(pt 2):I-241. Abstract.87. Zhong S, Sharp D S, Grove J S, Bruce C, Yano K, et al. 1996. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97:2917-23.88. Calle E E, Thun M J, Petrelli J M, Rodriguez C, Heath C W, Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-105.89. Agellon L B et al. Organization of the human cholesteryl ester transfer protein gene. Biochemistry 29: 1372-6, 1990.90. Drayna D et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 327 (6123): 632-4, 1987.91. Lusis A J et al. Assignment of the human gene for human cholesteryl ester transfer protein to chromosome 16q12-16q21. Genomics 1: 232-5, 1987.92. U.S. Pat. No. 6,313,142 B1, issued Nov. 6, 2001, Damon et al.93. U.S. Pat. No. 6,197,786 B1, issued Mar. 6, 2001, DeNinno et al.94. U.S. Patent Application Publication No. US2002/0177716 A1, published Nov. 28, 2002, Damon et al., issued as U.S. Pat. No. 6,689,897 B2, Feb. 10, 2004.95. U.S. Patent Application Publication No. US2002/0042364 A1, published Apr. 11, 2002, Rittershaus et al.96. Sun S. Technology evaluation: SELEX, Gilead Sciences Inc. Curr. Opin. Mol. Ther. 2: 100-5, 2000.97. Ashrafi K et al. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulation genes. Nature 421 (6920): 268-72, 2003.98. Hesler C B et al. Monoclonal antibodies to the Mr 74,000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma. J Biol. Chem. 1988 Apr. 15; 263(11):5020-3.99. Yen Ft et al. Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody. Effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma. J Clin Invest. 1989 June; 83(6):2018-24.100. Wang S et al. Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing monoclonal antibody and necessary for neutral lipid transfer activity. J Biol. Chem. 1992 Sep. 5; 267(25):17487-90.101. Williams S et al. Sequencing of the cholesteryl ester transfer protein 5′ regulatory region using artificial transposons. Gene 197: 101-107, 1997.102. Klerkx A. H. E. M. et al. Haplotype analysis of the CETP gene: not Taq1B but the closely linked -629C→A polymorphism and a novel promoter variant are independently associated with CETP concentration. Human Molecular Genetics 12(2): 111-123, 2003.103. Fumeron F et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J. Clin. Invest. 96(3): 1664-71, 1995.104. Corbex M et al. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. Genet. Epidemiol. 19: 64-80, 2000.105. Kuivenhoven J A et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. New Engl. J. Med. 338:86-93, 1998.106. Bernard S et al. Association between plasma HDL-cholesterol concentration and Taq1B CETP gene polymorphism in non-insulin-dependent diabetes mellitus. J. Lipid Res. 39: 59-65, 1998.107. Ordovas J M et al. Association of cholesteryl ester transfer protein-Taq1B polymorphism with variation in lipoprotein subclasses and coronary heart disease risk. The Framingham Study. Arterioscler. Thromb. Vasc. Biol. 20: 1323-9, 2000.108. Dachet C. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels. Role of Sp1/Sp3 in transcriptional regulation. Arterioscler. Thromb. Vasc. Biol. 20: 507-515, 2000.109. Couture P, Otvos J D, Cupples A, et al. Association of the C-514T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profiles: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2000; 20:815-822.110. Grundy S M, Vega G L, Otvos J D, Rainwater D L, Cohen J C. Hepatic lipase influences high density lipoprotein subclass distribution in normotriglyceridemic men: genetic and pharmacological evidence. J Lipid Res 1999; 40:229-234.111. Runsey S C, Galeano N F, Arad Y, Deckelbaum R J. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J Lipid Res 1992; 33:1551-61.112. Falconer, D S, and Mackay T F C. Introduction to Quantitative Genetics. Essex, UK: Addison Wesley Longman, 1996.113. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001; 16:285:2486-97.114. Lakka H M, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288:2709-2716.115. Reaven G M. Role of insulin resistance in human disease (Banting lecture). Diabetes. 1988; 37:1595-1607.116. Garvey W T, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003; 52:453-462.117. Nieves D J, Cnop M, Retzlaff B, Walden C E, Brunzell J D, Knopp R H, Kahn S E. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 2003 January; 52(1):172-9.118. DeFronzo R A. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997; 50:191-7.119. Despres J P, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J. Med. 1996; 334:952-7.120. Copeland G P, Leinster S J D, J. C., Hipkin L J. Insulin resistance in patients with colorectal cancer. Br J. Surg. 1987; 74:1031-5.121. Facchini F S, Hua N, Abbasi F, Reaven G M. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab. 2001 August; 86(8):3574-8.122. Stoll B A. Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr. 1999; 53:83-7.123. Chow W-H, Gridley G, Fraumeni J F, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J. Med. 2000; 343:1305-11.124. Jong M C, Rensen P C, Dahlmans V E, van der Boom H, van Berkel T J, Havekes L M. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res. 2001 October; 42(10):1578-85.125. Chhabra S, Narang R, Krishnan L R, Vasisht S, Agarwal D P, Srivastava L M, Manchanda S C, Das N. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet. 2002 Jun. 6; 3(1):9. Epub 2002 Jun 6.126. Minihane A M, Finnegan Y E, Talmud P, Leigh-Firbank E C, Williams C M. Influence of the APOC3-2854T>G polymorphism on plasma lipid levels: effect of age and gender. Biochim Biophys Acta. 2002 Aug. 8; 1583(3):311-4.127. Waterworth D M, Talmud P J, Luan J, Flavell D M, Byrne C D, Humphries S E, Wareham N.J. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta. 2003 Apr. 17; 1637(3):200-6.128. Dammerman M, Sandkuijl L A, Halaas J L, Chung W, Breslow J L. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA. 1993 May 15; 90(10):4562-6.129. Hegele R A, Connelly P W, Hanley A J, Sun F, Harris S B, Zinman B. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol. 1997 November; 17(11):2753-8.130. Anisimov S V, Volkova M V, Lenskaya L V, Khavinson V K, Solovieva D V, Schwartz E1. Age-associated accumulation of the apolipoprotein C-III gene T-455C polymorphism C allele in a Russian population. J Gerontol A Biol Sci Med Sci. 2001 January; 56(1):B27-32.131. Breyer E D, Le N A, Li X, Martinson D, Brown W V. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size. J Lipid Res. 1999 October; 40(10):1875-82.132. Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Geloën, A., Evens, P., Cervera, P., Le Bouc, Y., 2003. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421, 182-187.133. Krassas G E, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen J W, Flyvbjerg A: Free and total insulin-like growth factor (IGF)-I, -II and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J. Clin. Endocrinol. Metab. 88:132-135, 2003.134. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002 Aug. 20; 106(8):939-44.135. Gamero P, Sornay-Rendu E, Delmas P D. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet. 2000 Mar. 11; 355(9207):898-9.136. Harman S M, Metter E J, Blackman M R, Landis P K, Carter H B; Baltimore Longitudinal Study on Aging. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab. 2000 November; 85(11):4258-65.137. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman U H, Egevad L, Riboli E, Hallmans G, Kaaks R. Plasma insulin-like growth factor-1, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000 Dec. 6; 92(23):1910-7.138. Toniolo P, Bruning P F, Akhmedkhanov A, Bonfrer J M, Koenig K L, Lukanova A, Shore R E, Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer. Int J Cancer. 2000 Dec. 1; 88(5):828-32.139. Giovannucci E, Pollak M, Platz E A, Willett W C, Stampfer M J, Majeed N, Colditz G A, Speizer F E, Hankinson S E. Insulin-like growth factor I (IGF-1), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. Growth Horm IGF Res. 2000 April; 10 Suppl A:S30-1.140. Chan J M, Stampfer M J, Ma J, Gann P, Gaziano J M, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002 Jul. 17; 94(14):1099-106.141. Hankinson S E, Willett W C, Colditz G A, Hunter D J, Michaud D S, Deroo B, Rosner B, Speizer F E, Pollak M. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet. 1998 May 9; 351(9113):1393-6.142. Zhao H, Grossman H B, Spitz M R, Lerner S P, Zhang K, Wu X. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol. 2003 February; 169(2):714-7.143. Sandhu M S, Heald A H, Gibson J M, Cruickshank J K, Dunger D B, Wareham N J. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet. 2002 359(9319): 1740-5.144. Longo, V., Finch, C., 2003. Evolutionary medicine: from dwarf model systems to healthy centenarians? Science 299, 1342-1345.145. Pajvani U B, Scherer P E. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep. 2003 June; 3(3):207-13. Review.146. Diez J J, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003 March; 148(3):293-300. Review.147. Kenyon, C., 2001. A conserved regulatory system for aging. Cell 105, 165-168.148. Khosravi M J, Diamandi A, Mistry J, Lee P D K: A non-competitive ELISA for serum insulin-like growth factor-1. Clin Chem 42: 1147-1154, 1996.149. Lee P D K, Powell D, Baker B, Liu F, Mathew G, Levitsky I, Gutierrez O D, Hintz R L: Characterization of a direct, non-extraction immunoradiometric assay for free IGF-I. Presented at the 76th annual meeting of the Endocrine Society, Anaheim, 1994 (abstract #939).150. Haddad, I. A., Ordovas, J. M., Fitzpatrick, T. and Karathanasis, S. K. Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III, and A-IV genes. J. Biol. Chem. 261 (28), 13268-13277 (1986).151. U.S. Pat. No. 5,869,330, issued Feb. 9, 1999, Scherer et al.152. Groenendijk M, Cantor R M, de Bruin T W, Dallinga-Thie G M (2001) The apoAI-CIII-AIV gene cluster. Atherosclerosis 157: 1-11.153. Chobanian A V, Bakris G L, Black H R, Cushman W C, Green L A, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572.154. Karathanasis S K. Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes. Proc Natl Acad Sci USA 82:6374-78, 1985.155. Garasto S, Rose G, Derango F, Berardelli M, Corsonello A, et al. (2003) The study of APOA1, APOC3 and APOA4 variability in healthy ageing people reveals another paradox in the oldest old subjects. Ann Hum Genet 67: 54-62.156. Panza F, D'Introno A, Colacicco A M, Capurso C, Capurso S, et al. (2004) Vascular genetic factors and human longevity. Mech Ageing Dev 125: 169-178.157. Wang C S, McConathy W J, Kloer H U, Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75: 384-390.158. Kashyap M L, Srivastava L S, Hynd B A, Gartside P S, Perisutti G (1981) Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia. J Lipid Res 22: 800-810.159. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow J L. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249:790-3, 1990.160. Maeda N, Li H, Lee D, Oliver P, Quarfordt S H, et al. (1994) Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 269: 23610-23616.161. Takahashi T, Hirano T, Okada K, Adachi M (2003) Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice. Metabolism 52: 1354-1359.162. van Duijn C M, de Knijff P, Cruts M, et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet 1994; 7(1):74-8.163. Cnop M, Havel P J, Utzschneider K M, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46(4):459-69.164. Pollin T I, Tanner K, O'Connell J R, et al. Linkage of Plasma Adiponectin Levels to 3q27 Explained by Association With Variation in the APMI Gene. Diabetes 2005; 54(1):268-74.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"}},"description_lang":["en"],"has_description":true,"has_docdb":true,"has_inpadoc":true,"has_full_text":true,"biblio_lang":"en"},"jurisdiction":"US","collections":[],"usersTags":[],"lensId":"006-056-504-351-981","publicationKey":"US_7491543_B2","displayKey":"US 7491543 B2","docAssets":{"lensId":"006-056-504-351-981","pdfUrl":"https://www.lens.org/images/patent/US/7491543/B2/US_7491543_B2.pdf","images":[{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000001.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000001.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000002.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000002.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000003.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000003.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000004.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000004.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000005.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000005.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000006.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000006.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000007.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000007.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000008.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000008.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000009.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000009.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000010.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000010.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000011.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000011.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000012.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000012.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000013.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000013.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000014.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000014.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000015.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000015.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000016.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000016.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000017.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000017.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000018.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000018.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000019.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000019.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000020.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000020.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000021.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000021.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000022.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000022.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000023.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000023.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000024.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000024.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000025.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000025.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000026.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000026.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000027.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000027.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000028.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000028.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000029.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000029.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000030.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000030.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000031.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000031.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000032.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000032.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000033.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000033.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000034.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000034.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000035.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000035.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000036.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000036.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000037.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000037.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000038.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000038.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000039.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000039.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000040.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000040.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000041.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000041.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000042.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000042.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000043.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000043.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000044.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000044.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000045.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000045.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000046.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000046.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000047.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000047.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000048.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000048.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000049.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000049.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000050.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000050.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000051.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000051.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000052.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000052.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000053.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000053.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000054.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000054.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000055.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000055.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000056.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000056.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000057.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000057.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000058.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000058.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/10pc/00000059.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/7491/7491543/image/page/full/00000059.png"}],"fallover":false},"countryName":"USA","inventorModel":{"inventors":[{"name":{"value":"BARZILAI NIR","valueNormalised":"Barzilai Nir"},"inventorship":null}],"inventorships":[],"unmatchedInventorships":[],"activeUserHasInventorship":false},"simpleFamilyId":196693999,"citesPatentCount":0,"countrySpec":{"countryName":"USA","description":"GRANTED PATENT AS SECOND PUBLICATION [FROM 2001 ONWARDS]","rule":"pubdate:AFTER:01-01-2001","docType":"GRANTED_PATENT"},"pageTitle":"US 7491543 B2 - Biological markers for longevity and diseases and uses thereof","documentTitle":"Biological markers for longevity and diseases and uses thereof"},"claims":{"source":"xml_claims","claims":[{"lines":["A method of determining a subject's likelihood of longevity, likelihood of developing a cardiovascular related disease, likelihood of developing a metabolic syndrome, or likelihood of retaining cognitive function during aging, wherein the cardiovascular related disease is selected from the group consisting of hypertension, diabetes mellitus, myocardial infarction, stroke and transient ischemic attack,\n
the method comprising comparing high density lipoprotein (HDL) particle size from the subject's plasma with high density lipoprotein (HDL) particle size from a control population,\n
wherein an average size of the subject's high density lipoprotein (HDL) particles that is statistically significantly larger than an average size of high density lipoprotein (HDL) particles from the control population indicates that the subject has an increased likelihood of longevity, a decreased likelihood of developing a cardiovascular related disease, a decreased likelihood of developing a metabolic syndrome or an increased likelihood of retaining cognitive function during aging, or\n
wherein an average size of the subject's high density lipoprotein (HDL) particles that is statistically significantly smaller than an average size of high density lipoprotein (HDL) particles from the control population indicates that the subject has an increased likelihood of developing a cardiovascular related disease or an increased likelihood of developing a metabolic syndrome."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which comprises determining a subject's likelihood of longevity."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which comprises determining a subject's likelihood of developing a cardiovascular related disease."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which comprises determining a subject's likelihood of developing a metabolic syndrome."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which comprises determining a subject's likelihood of retaining cognitive function during aging."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which further comprises comparing the number of large size HDL particles as a percentage of total HDL particles from the subject with the percentage of large size HDL particles from the control population, wherein large size HDL particles have a diameter of 8.8-13 nm, and\n
wherein a statistically significant greater number of large size HDL particles as a percentage of total HDL particles from the subject than from the control population indicates that the subject has an increased likelihood of longevity, a decreased likelihood of developing a cardiovascular related disease, a decreased likelihood of developing a metabolic syndrome or an increased likelihood of retaining cognitive function during aging, or\n
wherein a statistically significant smaller number of large size HDL particles as a percentage of total HDL particles from the subject than from the control population indicates that the subject has an increased likelihood of developing a cardiovascular related disease or an increased likelihood of developing a metabolic syndrome."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which further comprises comparing the number of medium size HDL particles as a percentage of total HDL particles from the subject with the percentage of medium size HDL particles from the control population, wherein medium size HDL particles have a diameter of 8.2-8.8 nm and wherein a statistically significant smaller number of medium size HDL particles as a percentage of total HDL particles from the subject than from the control population indicates that the subject has an increased likelihood of longevity."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the subject's high density lipoprotein (HDL) particles have an average size that is at least 2% greater than that of high density lipoprotein (HDL) particle average size from the control population."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the subject's high density lipoprotein (HDL) particles have an average size that is at least 2% smaller than that of high density lipoprotein (HDL) particle average size from the control population."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the subject's high density lipoprotein (HDL) particles have an average size that is at least 0.2 nm larger in diameter than that of high density lipoprotein (HDL) particle average size from the control population."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the subject and the control population are the same gender."],"number":11,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}